| MeSH term | MeSH ID | Detail |
|---|---|---|
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
Total
3
Norethindrone
Norethindrone is a lipid of Sterol Lipids (ST) class. Norethindrone is associated with abnormalities such as Endometriosis, site unspecified, Wiskott-Aldrich Syndrome and Estrogenic effect. The involved functions are known as Hemorrhage, Phosphorylation, Apoptosis, DNA Repair and Cell Cycle. Norethindrone often locates in Blood, Back, Body tissue, Nucleolar and Human tissue. The associated genes with Norethindrone are MMP gene, NR3C1 gene and Genes, Reporter. The related lipids are Steroids, 4,17 beta-dihydroxy-4-androstene-3-one, 4-estren-3,17-diol and Estranes.
Cross Reference
Introduction
To understand associated biological information of Norethindrone, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Norethindrone?
Norethindrone is suspected in Endometriosis, site unspecified, Estrogenic effect and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Norethindrone
PubChem Associated disorders and diseases
What pathways are associated with Norethindrone
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Norethindrone?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Norethindrone?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Norethindrone?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Norethindrone?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Norethindrone?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with Norethindrone
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Kalay AE et al. | Efficacy of citalopram on climacteric symptoms. | 2007 Mar-Apr | Menopause | pmid:17224858 |
| Rubinacci A et al. | Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women. | 2003 May-Jun | Menopause | pmid:12792297 |
| Ventura P et al. | Continuous combined hormone replacement therapy with oral 17beta-estradiol and norethisterone acetate improves homocysteine metabolism in postmenopausal women. | 2001 Jul-Aug | Menopause | pmid:11449082 |
| Naessen T et al. | Early postmenopausal hormone therapy improves postural balance. | 2007 Jan-Feb | Menopause | pmid:17091024 |
| Krämer EA et al. | The effects of progesterone, medroxyprogesterone acetate, and norethisterone on growth factor- and estradiol-treated human cancerous and noncancerous breast cells. | 2005 Jul-Aug | Menopause | pmid:16037763 |
| Battaglia C et al. | Angeliq versus Activelle in normotensive postmenopausal women: a prospective, randomized pilot study. | 2009 Jul-Aug | Menopause | pmid:19194341 |
| Al-Azzawi F et al. | Bone mineral density in postmenopausal women treated with a vaginal ring delivering systemic doses of estradiol acetate. | 2005 May-Jun | Menopause | pmid:15879923 |
| Shakir YA et al. | Combined hormone therapy in postmenopausal women with features of metabolic syndrome. Results from a population-based study of Swedish women: Women's Health in the Lund Area study. | 2004 Sep-Oct | Menopause | pmid:15356408 |
| Speroff L et al. | The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms. | 2000 Nov-Dec | Menopause | pmid:11127760 |
| Birge SJ | Nonvertebral "osteoporotic" fractures: a brain disease or bone disease? | 2007 Jan-Feb | Menopause | pmid:17179791 |
| Cagnacci A et al. | Transdermal administration of estradiol and norethisterone: effect on the uterus and uterine arteries. | 2000 Mar-Apr | Menopause | pmid:10746894 |
| Brynhildsen J and Hammar M | Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women. | 2002 Mar-Apr | Menopause | pmid:11875333 |
| Liang Y et al. | Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice. | 2010 Sep-Oct | Menopause | pmid:20461021 |
| Greenwald MW et al. | Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. | 2005 Nov-Dec | Menopause | pmid:16278618 |
| Hofling M et al. | Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. | 2007 Mar-Apr | Menopause | pmid:17108847 |
| Christodoulakos GE et al. | The effect of hormone therapy and raloxifene on serum matrix metalloproteinase-2 and -9 in postmenopausal women. | 2004 May-Jun | Menopause | pmid:15167309 |
| Rolnick SJ et al. | Hormone use and patient concerns after the findings of the Women's Health Initiative. | 2005 Jul-Aug | Menopause | pmid:16037754 |
| Mueck AO et al. | Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. | 2007 Nov-Dec | Menopause | pmid:17595593 |
| Price T | Progesterone receptor membrane component 1: is metabolism integral to its function and what other steroids are involved? | 2013 | Menopause | pmid:23511707 |
| Dören M et al. | Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. | 1999 | Menopause | pmid:10614676 |
| Samsioe G et al. | Changes in lipid and lipoprotein profile in postmenopausal women receiving low-dose combinations of 17beta-estradiol and norethisterone acetate. | 2002 Sep-Oct | Menopause | pmid:12218722 |
| Mueck AO et al. | Medroxyprogesterone acetate versus norethisterone: effect on estradiol-induced changes of markers for endothelial function and atherosclerotic plaque characteristics in human female coronary endothelial cell cultures. | 2002 Jul-Aug | Menopause | pmid:12082363 |
| Walker RJ et al. | The effects of sequential combined oral 17beta-estradiol norethisterone acetate on insulin sensitivity and body composition in healthy postmenopausal women: a randomized single blind placebo-controlled study. | 2001 Jan-Feb | Menopause | pmid:11201511 |
| Seeger H et al. | Effect of medroxyprogesterone acetate and norethisterone on serum-stimulated and estradiol-inhibited proliferation of human coronary artery smooth muscle cells. | 2001 Jan-Feb | Menopause | pmid:11201515 |
| Ursic-Vrscaj M et al. | Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. | 2001 Jan-Feb | Menopause | pmid:11201519 |
| Hemelaar M et al. | Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial. | 2008 Mar-Apr | Menopause | pmid:17693902 |
| Botteman MF et al. | A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms. | 2004 May-Jun | Menopause | pmid:15167315 |
| Mitwally MF et al. | Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. | 2002 Jul-Aug | Menopause | pmid:12082359 |
| Zegura B et al. | The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. | 2006 Jul-Aug | Menopause | pmid:16837886 |
| Vitale C et al. | Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. | 2005 Sep-Oct | Menopause | pmid:16145309 |
| Rinaldi M et al. | Neutral effect of prolonged transdermal hormone therapy on liver function of postmenopausal women with chronic active hepatitis. | 2005 Sep-Oct | Menopause | pmid:16145317 |
| Georgiev DB and Manassiev NA | Effect of long-term continuous combined hormone replacement therapy with estradiol valerate and either dienogest or norethisterone acetate on mammographic density in postmenopausal women. | 2002 Jul-Aug | Medscape Womens Health | pmid:12466733 |
| Kyriakou A and Skordis N | Thalassaemia and aberrations of growth and puberty. | 2009 | Mediterr J Hematol Infect Dis | pmid:21415985 |
| Czarnecka D et al. | The effect of hormone replacement therapy on endothelial function in postmenopausal women with hypertension. | 2004 | Med. Sci. Monit. | pmid:14737044 |
| Gattanell PN et al. | Hepatocellular carcinoma in a young woman with prolonged exposure to oral contraceptives. | 1978 | Med. Pediatr. Oncol. | pmid:207962 |
| Stoll BA | Therapy by progestational agents in advanced breast cancer. | 1966 | Med. J. Aust. | pmid:5906684 |
| CUNINGHAM K and LANG WR | Result of a blind clinical trial conducted on 50 cases of hormonal mastopathy. | 1962 | Med. J. Aust. | pmid:14024258 |
| Roxburgh DR and West MJ | The use of norethisterone to suppress menstruation in the intellectually severely retarded woman. | 1973 | Med. J. Aust. | pmid:4746398 |
| Kneale B and Evans J | Progestogen therapy for advanced carcinoma of the endometrium. | 1969 | Med. J. Aust. | pmid:5374044 |
| Fraser IS and Weisberg E | A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate. | 1981 | Med. J. Aust. | pmid:6453269 |
| MacLennan AH et al. | Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial. | 1993 | Med. J. Aust. | pmid:8336583 |
| PLANT GH | PRODUCTION AND QUALITY CONTROL OF AN ORAL CONTRACEPTIVE. | 1965 | Med. J. Aust. | pmid:14265218 |
| BROWN MM | PREMENSTRUAL METATARSALGIA. | 1965 | Med. J. Aust. | pmid:14315259 |
| Wren BG | Minimal dose combined hormonal replacement therapy for menopausal women. | 1981 | Med. J. Aust. | pmid:7242418 |
| GOLDZIEHER JW | NEWER DRUGS IN ORAL CONTRACEPTION. | 1964 | Med. Clin. North Am. | pmid:14149247 |
| Ranneberg KM and Holzmann H | [Herpes gestationis recurrence caused by synthetic gestagens]. | 1970 | Med Welt | pmid:4249079 |
| HEINEN G | [Oral contraception]. | 1962 | Med Welt | pmid:13953432 |
| GOLDFARB AF et al. | OVULATION CONTROL. | 1963 | Med Sci | pmid:14081010 |
| DEHAEN P | THERAPEUTIC RESEARCH IN REVIEW. | 1964 | Med Sci | pmid:14143127 |
| Zaffaroni A | Systems for controlled drug delivery. | 1981 | Med Res Rev | pmid:7050567 |